

Transfer of cannabinoids into the milk of dairy cows fed with industrial hemp could lead to Δ^9 -THC exposure that exceeds acute reference dose

Received: 25 April 2022

Accepted: 26 September 2022

Published online: 14 November 2022

 Check for updates

Bettina Wagner¹✉, Pietro Gerletti¹, Peter Fürst², Oliver Keuth², Thorsten Bernsmann², Annett Martin¹, Bernd Schäfer¹, Jorge Numata¹, Marc C. Lorenzen¹ & Robert Pieper¹✉

The industrial hemp sector is growing and, in recent years, has launched many novel hemp-derived products, including animal feed. It is, however, unclear to what extent individual cannabinoids from industrial hemp transfer from the feed into products of animal origin and whether they pose a risk for the consumer. Here we present the results of a feeding experiment with industrial hemp silage in dairy cows. Hemp feeding included changes in feed intake, milk yield, respiratory and heart rates, and behaviour. We combined liquid chromatography–tandem mass spectrometry-based analyses and toxicokinetic computer modelling to estimate the transfer of several cannabinoids (Δ^9 -tetrahydrocannabinol (Δ^9 -THC), Δ^8 -THC, Δ^9 -tetrahydrocannabinolic acid, Δ^9 -tetrahydrocannabivarin, 11-OH- Δ^9 -THC, 11-nor-9-carboxy- Δ^9 -THC, cannabidiol, cannabinol and cannabidivarin) from animal feed to milk. For Δ^9 -THC, which has a feed-to-milk transfer rate of $0.20\% \pm 0.03\%$, the acute reference dose for humans was exceeded in several consumer groups in exposure scenarios for milk and dairy product consumption when using industrial hemp to feed dairy cows.

A global ban during the first half of the 20th century saw hemp (*Cannabis sativa*) production relegated to the sidelines of industry and agriculture, despite its potential as a cheap, ecological and versatile crop¹. The recent revision of cannabis regulations has triggered a fast-paced growth in the industrial hemp sector which has brought to the market many novel hemp-derived products^{1,2}. This proliferation raises consumer safety issues because hemp contains cannabinoids, a class of substances that interact with the animal and human endocannabinoid system. Some of them—especially Δ^9 -tetrahydrocannabinol (Δ^9 -THC)—exert a psychoactive effect and

others are only pharmacologically active, such as cannabidiol (CBD)³. Cultivation of industrial hemp with a maximum Δ^9 -THC content of 0.2% is allowed in the European Union⁴. In 2021, an increase to 0.3% was initiated in the European Union⁵.

A transfer of cannabinoids into foods of animal origin is conceivable when by-products of hemp production and the whole plant are used as feedstuffs⁶. So far, despite a few case reports, experimental data regarding the transfer of Δ^9 -THC from feed into the milk of cows are scarce and analytical techniques often failed to differentiate between psychoactive Δ^9 -THC and its non-psychoactive precursor

¹German Federal Institute for Risk Assessment (BfR), Berlin, Germany. ²Chemical and Veterinary Analytical Institute Münsterland-Emscher-Lippe (CVUA-MEL), Münster, Germany. ✉e-mail: Bettina.Wagner@bfr.bund.de; Robert.Pieper@bfr.bund.de

Δ^9 -tetrahydrocannabinolic acid (Δ^9 -THCA)⁶. Given that Δ^9 -THCA can be up to nine times more abundant than Δ^9 -THC in hemp⁷, this differentiation is crucial to understand transfer processes and subsequently perform risk analysis.

In this article, we focus on the effects of industrial hemp silage feeding in lactating dairy cows with the aim of quantifying the transfer of cannabinoids into milk and determining possible effects on animal health and risks for consumer health. We collected and analysed milk, blood plasma and faeces, measured physiological parameters and observed animal behaviour. We employ a liquid chromatography–tandem mass spectrometry-based analytical technique that ensures differentiation between Δ^9 -THC and Δ^9 -THCA in various matrices, and enables quantification of the cannabinoids Δ^8 -tetrahydrocannabinol (Δ^8 -THC), Δ^9 -tetrahydrocannabivarin (Δ^9 -THCV), CBD, cannabinol (CBN), cannabidivarin (CBDV) and the two Δ^9 -THC metabolites 11-hydroxy- Δ^9 -THC (11-OH-THC) and 11-nor-9-carboxy- Δ^9 -THC (THC-COOH). The resulting data were used to develop a predictive toxicokinetic model, which can be used to simulate other exposure scenarios and to assess the transfer of different cannabinoids into cows' milk when using industrial hemp as a dietary supplement for dairy cows.

Results and discussion

We conducted a feeding experiment with lactating Holstein Friesian dairy cows, where corn silage in the diet was first partially replaced with hemp silage made from whole plant hemp (very low cannabinoid concentration, hemp silage A) during an adaptation period followed by feeding hemp silage made from leaves, flowers and seeds only (higher cannabinoid concentration, hemp silage E) at two different supplementation levels (group L, low hemp, 0.84 kg dry matter per cow per day; group H, high hemp, 1.68 kg dry matter per cow per day) during an exposure period, and a subsequent hemp-free depuration period (Fig. 1a). Partial replacement of corn silage with hemp silage of different nutritional composition also partially changed the total nutritional composition of the diets; however, the major difference was in total cannabinoid concentration (Table 1 and Supplementary Table 1).

Feeding industrial hemp can affect animal health

The study shows that feeding up to 0.92 kg per cow per day (DM, dry matter) of industrial hemp silage A with very low cannabinoid concentration to dairy cows during the adaptation period had no effect on physiological parameters and health (Fig. 1b–e; see Supplementary Table 2 and Supplementary Fig. 1 for statistical data).

In contrast, feeding of cannabinoid-rich industrial hemp silage E during the exposure period had a significant effect for both group L and group H. A Kruskal–Wallis test showed that feed intake ($\chi^2 = 28.9$, $P < 0.001$, d.f. = 5) and consequently milk yield ($\chi^2 = 44.5$, $P < 0.001$, d.f. = 5) decreased significantly from the second day of exposure period in both experimental groups (Fig. 1b,c). The average ingested doses of Δ^9 -THC and CBD were 1.6 ± 0.3 and 10.7 ± 1.9 mg per kg body weight for group L, and 3.1 ± 0.7 and 20.4 ± 4.4 mg per kg body weight for group H, whereas the dose of the other cannabinoids was ≤ 1.1 mg per kg body weight (Supplementary Table 3). Similarly, the respiratory ($\chi^2 = 50.2$, $P < 0.001$, d.f. = 5) and heart rate ($\chi^2 = 77.4$, $P < 0.001$, d.f. = 5) decreased significantly within hours in both groups due to the feeding of hemp silage E (Fig. 1d,e) and in individual animals fell below physiological reference values, allowing classification as either bradypnea or

bradycardia. Concomitantly, changes in animal behaviour and appearance were evident (Fig. 1f), such as pronounced tongue play, increased yawning, salivation, nasal secretion formation, prolapse and reddening of the nictitating membrane, and somnolent appearance. Some animals from group H displayed careful, occasionally unsteady gait, unusually long standing and abnormal posture. All changes observed disappeared within two days of discontinuing cannabinoid feeding. Milk constituents (fat, protein, lactose, dry matter, somatic cell count and urea), body temperature and body weight were unaffected in all periods (Supplementary Tables 4 and 5).

For humans, the lowest-observed-adverse-effect-level for Δ^9 -THC is 0.036 mg per kg body weight⁶. On average, the cows ingested up to 86 times more Δ^9 -THC during the exposure period, probably explaining the health effects they exhibited. Another study in ruminants reported no health effects, although this involved feeding only 35 g of industrial hemp, a much lower exposure than the present study⁸. In animals, only a few studies have reported a reduction in feed consumption due to administration of Δ^9 -THC and CBD, whereas other studies showed no significant decrease or even an increase in feed consumption^{9–13}. Other factors in the silages, such as fermentation acids or lignin (Supplementary Table 6), may also have led to the drop in feed intake, but were not observed when feeding industrial hemp silage A during the adaptation period. In contrast, hemp silage E was markedly richer in fat, which could also have led to a reduction in feed intake¹⁴. Studies on the suitability of industrial hemp components, other than seeds and oil, as animal feed are rare¹⁵, complicating the interpretation of our results. The reduction in daily milk yield is presumably caused by the decrease in feed intake. A decrease in water consumption (not measured) due to cannabinoids in the feed may have promoted the decrease^{16–18}. Bradypnea and bradycardia are rare symptoms in cows that only occur in the course of serious illnesses or can be pharmacologically induced. In animal studies, administration of Δ^9 -THC (but not CBD) influenced respiratory and heart rate and caused drowsiness, slow movements, ataxia and salivation^{12,13,19–21}. A reddening of the conjunctiva after Δ^9 -THC intake is known in humans^{22,23}.

Although it is clear that the observed effects of industrial hemp silage feeding on animal health were mainly caused by the cannabinoids, it cannot be clearly defined which cannabinoid was responsible. Due to its high concentration in the cannabinoid-rich silage, Δ^9 -THC is the most likely cause, but combination effects may also play a role^{16,17,24,25}. Finally, it should be considered that hemp plants produce other phytochemicals (for example, terpenes, flavonoids) that may have an impact on the changes observed^{26,27}. Similarly, an effect due to minor changes in nutrient concentration of the diets by replacement of corn silage with hemp silage (Supplementary Table 1) could not be completely ruled out.

Our study shows that the feeding of industrial hemp silage to dairy cows, even in small amounts, is associated with health consequences. These seem to be dependent on the cannabinoid concentration of the silage, which is influenced by, among other factors, the variety, the parts of the plant from which the silage is derived and the time of harvest^{7,28}. Due to the manifold parameters influencing the cannabinoid concentration of hemp and derived feed, the innocuousness of hemp cannot be reliably assessed without prior cannabinoid analysis.

Fig. 1 | Study design and results of the feeding experiment. **a**, Study design and sampling strategy. Grey arrows represent sampling days, striped lines in arrows indicate no sampling for this parameter on that day. ^aAll animals per group ($n = 4$). ^bTwo animals per group. **b–e**, Feed intake (**b**), milk yield (**c**), respiratory rate (**d**) and heart rate (**e**) during the feeding experiment. Violin plots represent the density distribution; black error bars are the standard deviations of the means (black dot); red dots represent the median; blue dots (jittered) are raw data. Means followed by a common letter are not significantly different by a

Tukey test. *P* values (with *t* values and 95% confidence intervals for standardized effect size measures) are from multiple comparisons according to Tukey post hoc tests and are listed in Supplementary Table 2 and Supplementary Fig. 1. To show differences more clearly, standardized effect size measures of animal health parameters were plotted between time periods (pairwise comparisons) with 95% confidence intervals. **f**, Pictures of cows during exposure period: (1) prolapsed and reddened nictitating membrane; (2) increased salivation with ponding; (3) pronounced tongue play; (4) nasal secretion.

Cannabinoid transfer from feed to cow's milk

Feeding hemp silage resulted in measurable levels of Δ^9 -THC, Δ^9 -THCA, Δ^9 -THCV, CBD, CBN and CBDV in cow's milk at the end of the adaptation

period and during the exposure period. Concentrations of up to 316 μg Δ^9 -THC and 1,174 μg CBD were detected per kg milk (Fig. 2). Maximum values for other cannabinoids in milk were 1.9 (Δ^9 -THCA), 8.0 (Δ^9 -THCV),








Table 1 | Cannabinoid concentration (mg per kg dry matter) of the different hemp silages

Cannabinoid	Hemp silage	
	A (adaptation period)	E (exposure period)
Δ^9 -THC	58.3	1,254.7
Δ^8 -THC	<LOD	<LOD
Δ^9 -THCA	7.4	70.1
Δ^9 -THCV	0.2	12.5
11-OH-THC	<LOD	<LOD
THC-COOH	<LOD	<LOD
CBD	804.7	8,304.1
CBN	9.4	38.9
CBDV	5.1	450.1

Two different industrial hemp silages were used for the experiment. During the adaptation period, hemp silage A with low cannabinoid concentration was used. To achieve the low cannabinoid concentration, the whole plant (without roots) of the low Δ^9 -THC variety Ivory was used. For the exposure period, the cannabinoid-rich hemp silage E was used. For this silage, the variety Finola was selected as a representative of varieties with higher Δ^9 -THC concentration (but still below 0.2% total Δ^9 -THC) and only cannabinoid-rich plant parts (leaves, flowers, seeds) were used. LOD, limit of detection.

2.5 (CBN) and 10.1 μg per kg body weight (CBDV). On the last day of the depuration period, Δ^9 -THC (group L: 1.4 ± 0.4 μg per kg; group H: 5.0 ± 0.6 μg per kg) and CBD (group L: 7.0 ± 1.9 μg per kg; group H: 16.2 ± 2.6 μg per kg) were still detectable in milk. The other cannabinoids analysed were undetectable in milk during all periods (limit of detection (LOD): 0.1 μg per kg milk for Δ^8 -THC, 0.5 μg per kg milk for 11-OH- Δ^9 -THC and THC-COOH). At the end of the exposure period, the levels in milk were 6–26 times higher for Δ^9 -THC, 3–5 times higher for Δ^9 -THCV and 11–32 times higher for CBD than the corresponding blood plasma levels, pointing to the accumulation potential of the substances in cow's milk. In contrast, Δ^9 -THCA did not accumulate in milk and CBDV showed no clear trend (Supplementary Table 7). Since CBN was undetectable in plasma, no ratio could be calculated. Urine was collected during the experiment, but due to analytical challenges, that is, inconsistent results after glucuronidase treatment, the data could not be evaluated.

In contrast to an earlier study in Holstein calves in which only Δ^9 -THCA and traces of CBD could be detected in the plasma after hemp feeding⁸, we were able to detect Δ^9 -THC, Δ^9 -THCV, CBD and CBDV, presumably due to the higher dose. Studies on the transfer of cannabinoids from feed into milk are rare and, up to now, only Δ^9 -THC and THC-COOH have been found in ruminant milk after oral Δ^9 -THC-exposure^{29,30}. In humans, the transfer of Δ^9 -THC and CBD into breastmilk after marijuana use has been demonstrated, whereas 11-OH-THC and THC-COOH have not always been found^{31–33}. The wide range of reported milk/plasma ratios for Δ^9 -THC is consistent with an earlier study³¹.

Toxicokinetic model

We set up two-compartment models, as shown in Fig. 3a, with either two (model A) or one (model B) excretion outputs from the central compartment. Model A was used for Δ^9 -THC and CBD, for which enough data were available, and the simplified model B for the other cannabinoids with fewer data. The model reproduces milk data with a Pearson coefficient of determination r^2 of 0.92 (Supplementary Fig. 2). The model can approximate Δ^9 -THC and CBD plasma and faeces levels with a Pearson r^2 of 0.93 and 0.90, respectively, even though few data points were available. Figure 3b,e shows the relative fate of Δ^9 -THC and CBD, respectively. Only a small fraction ends up in milk, with most of the substance (77% Δ^9 -THC and 64% CBD) being 'eliminated' in processes such as putative metabolism, biochemical transformations in the gastrointestinal tract

and urinary excretion. This hints at a high bioavailability for the compounds, with 20–35% being excreted into faeces. Figure 3c,d (Δ^9 -THC) and Fig. 3e,f (CBD) show the milk predictive model, obtained using the average of the single model parameters estimates, plotted against the data of all animals in the experiment. The simulation was performed to simulate the same intake scenarios as in the experiment. The predictive models for Δ^9 -THC and CBD can predict the milk levels in each scenario (L/H) with an average underestimation between 12% and 26% for the exposure period. Nevertheless the model predictions are in line with the observed data range (Pearson r^2 between 0.59 and 0.88), such that they appear sufficient for risk assessment. Model B was successfully used to predict cannabinoid milk levels and to provide an estimate for the transfer rates at steady state. The figures showing the results for Δ^9 -THCA, Δ^9 -THCV, CBN and CBDV are included in Supplementary Fig. 3.

Both the data and the models show that cannabinoids display biphasic elimination: there is a rapid decline in milk levels following discontinuation of cannabinoid feeding and further decline over a longer period.

Cannabinoids are metabolized in the liver of mammals, where they undergo biotransformation. Our model lumps these processes into 'elimination' of the central compartment (model A) and total elimination (model B), without details. Having information on these processes would allow for a more refined model and unify the models for individual cannabinoids into a single one including interconversion. Such processes could be quantified using both in vivo and in vitro techniques. Finally, it should be noted that there is still no information on the fate of cannabinoids in the gastrointestinal tract of the cow prior to absorption.

Predictive model and transfer rates at steady state

The predictive model for each cannabinoid was used to estimate transfer rates at steady state for each substance. The transfer rate is defined as the daily amount of cannabinoids in milk divided by the amount in feed (μg μg^{-1}). For Δ^9 -THC at steady state, we estimate a milk transfer rate of 0.20%, or around 33–100% higher than reported in previous experiments^{6,29}. No data on cow's milk transfer rates for the other cannabinoids analysed was available from previous literature. We present here the milk transfer rates for Δ^9 -THCA (0.015%), Δ^9 -THCV (0.56%), CBD (0.11%), CBN (0.043%) and CBDV (0.0080%) in cows (Supplementary Table 8). The transfer rate of Δ^9 -THCA appears much lower than its decarboxylated counterpart Δ^9 -THC, which could mean lower bioavailability and/or that some of the Δ^9 -THCA does not reach the intestinal tract of the animal, but instead undergoes chemical reactions in the rumen (decarboxylation, bacterial metabolism). The latter putative processes are theoretically possible for each of the studied cannabinoids, as they have similar chemical structures and can potentially interconvert³⁴. Although Δ^9 -THCV has the highest transfer rate, the low concentrations found in hemp silages make it unlikely to pose a risk to consumers. Overestimation of its transfer rate through putative rumen processes cannot be ruled out. The transfer rate of CBD is in the same range as that of Δ^9 -THC. Since the CBD concentration in the silage was much higher, as usual for industrial hemp, this resulted in markedly higher milk levels. Thus, CBD may be as relevant as Δ^9 -THC when assessing consumer risks. CBN and CBDV showed the lowest transfer rates and very low levels in milk, confirming that Δ^9 -THC and CBD are the main compounds of interest for animal health and consumer safety.

Human exposure to Δ^9 -THC via milk may exceed the acute reference dose

The acute reference dose (ARFD) is an estimate of the amount of a substance in food and/or drinking water that can be ingested in a period of up to 24 h without appreciable health risk to the consumer³⁵. To obtain a rough estimate on the potential risk from exposure to Δ^9 -THC via milk containing levels as measured in the present study, a cursory toxicological assessment was conducted. The EFSA Rapid Assessment




Fig. 2 | Cannabinoid concentration in milk. Mean \pm s.d. Δ^9 -THC and CBD levels. Days 1–6 and 8–13: no milk samples analysed. *Data interpolated. During the experimental periods, milk samples were taken on days 7, 14–24, 26 and 28 from both groups L and H ($n = 4$ per group) for cannabinoid analysis. To compile a

sample for analysis, the evening and the following morning milk of each cow were mixed according to their proportion of daily production. The resulting composite samples were stored at -20°C until HPLC–MS/MS analysis.

of Contaminant Exposure (RACE) software tool³⁵ was used to estimate the exposure to Δ^9 -THC resulting from consumption of milk and dairy products, considering the measured Δ^9 -THC levels, and was then compared to the acute reference dose (ARfD) of $1\ \mu\text{g}\ \Delta^9$ -THC per kg body weight derived by EFSA⁶.

For mean and maximum Δ^9 -THC concentrations in milk from group L, average consumption of milk and dairy products leads to the ARfD being exceeded by up to 14-fold for consumers aged <18 yr, whereas high consumption (95th percentile) exceeds the ARfD up to 57-fold in all population groups. Based on the mean and maximum Δ^9 -THC levels in milk from group H, the ARfD is exceeded up to 120-fold for all population groups (Table 2). Remarkably, even consumption of milk and dairy products from the adaptation period (lowest Δ^9 -THC in feed) leads to the ARfD being exceeded by 1.5-fold in infant high consumers (95th percentile). Additionally, it should be taken into account that Δ^9 -THCA present in milk could be converted into Δ^9 -THC during processing of the milk (for example, ultrahigh-temperature processing)⁶.

Thus, the exposure scenario based on the data obtained from the transfer study presented herein shows that exposure to Δ^9 -THC via milk and dairy products could lead to the ARfD being exceeded in some consumer groups.

Comparison with the Community method for determination of Δ^9 -THC

We compared our analytical approach to the Community method for the quantitative determination of Δ^9 -THC content in hemp varieties, which is laid down in Annex III of Regulation (EU) Number 639/2014. The approaches differ substantially in extraction method, extraction time, extraction solvent and analytical determination. The Community

method uses hexane containing squalane as an internal standard in an ultrasonic bath for extraction, and without further clean-up steps, the analytical separation and determination is performed isothermally by gas chromatography with flame ionization detection (GC-FID). This method has drawbacks: the extraction of Δ^9 -THC and Δ^9 -THCA is not complete, and their separate determination is not possible. Additionally, Δ^9 -THCA may be converted in the GC injector into Δ^9 -THC. Moreover, coelution of Δ^9 -THC with other cannabinoids or coextractives of hemp due to the limited clean-up of the crude sample extract and the isothermal GC conditions cannot be excluded. These drawbacks are overcome by our approach. The use of a Soxhlet apparatus enables an almost exhaustive extraction by repeatedly adding freshly dripping solvent, avoiding saturation. In preliminary tests, acetone was found to be more suitable than *n*-hexane for extraction of Δ^9 -THC and Δ^9 -THCA. By using the Community method, the total THC (the sum of Δ^9 -THC and Δ^9 -THCA) was 21 and 186 mg per kg DM, respectively for the two industrial hemp silages. In contrast, our new method yielded 65 and 1,317 mg per kg DM, respectively. Analytical determination using high-performance liquid chromatography coupled to tandem mass spectrometry (HPLC–MS/MS) with isotope-labelled internal standards enables the unequivocal separation and identification not only of Δ^9 -THC and its precursor but also of further cannabinoids at low limits of quantification. Therefore, we question the sensitivity of the Community method when used to determine the actual total THC concentration in hemp.

Conclusion

Our study shows that feeding cannabinoid-rich industrial hemp silage made from leaves, flowers and seeds leads to a decrease in feed intake and milk yield in dairy cows. Heart rate, respiratory rate and animal

Fig. 3 | Overview of the modelling results. **a**, Model structure schema. Model A (used for Δ^9 -THC and CBD) has three output routes: faeces, elimination and milk. Model B (used for the other cannabinoids) is a simplification of model A, with only two outputs: total elimination and milk. **b**, Modelled fractions of Δ^9 -THC output. Most Δ^9 -THC is eliminated, some is excreted with faeces with only a small amount found in milk. **c, d**, Predictive model of Δ^9 -THC excretion in milk for group L (**c**) and group H (**d**). The plots show the Δ^9 -THC amount (mg d^{-1}) excreted in

milk against the experimental data of the cows in the group, in a simulation of the experiment with low (**c**) and high (**d**) dose. **e**, Modelled fractions of CBD output. Compared to Δ^9 -THC, CBD is excreted in higher amounts in the faeces, hinting to lower bioavailability. **f, g**, Predictive model of CBD excretion in milk for group L (**f**) and group H (**g**). The plots show the CBD amount (mg d^{-1}) excreted in milk against the experimental data of the cows in the group, in a simulation of the experiment with low (**f**) and high (**g**) dose.

behaviour were also negatively affected. Feeding a low-cannabinoid industrial hemp silage made from the whole hemp plant showed no effects on cow health and performance. However, apart from dietary

cannabinoids, other factors due to partial replacement of corn silage with industrial hemp silage in this experiment (that is, change in nutrient composition, other secondary plant compounds) could not




Table 2 | Comparison of the exposure to Δ^9 -THC and the ARfD for different population groups

Population group	Average consumer					High consumer (95th percentile)				
	Δ^9 -THC concentration in cow's milk ($\mu\text{g kg}^{-1}$)					Δ^9 -THC concentration in cow's milk ($\mu\text{g kg}^{-1}$)				
	Groups L+H Adaptation period	Group L Exposure period		Group H Exposure period		Groups L+H Adaptation period	Group L Exposure period		Group H Exposure period	
	Mean 4.0	Mean 94.2	Max. 152.0	Mean 201.7	Max. 316.0	Mean 4.0	Mean 94.2	Max. 152.0	Mean 201.7	Max. 316.0
Infants (< 1 year)	0.36	8.6	14	18	29	1.5	35	57	75	120
Toddlers (≥ 1 to < 3 years)	0.15	3.5	5.7	7.5	12	0.35	8.3	13	18	28
Other children (≥ 3 to < 10 years)	0.13	3.1	5.0	6.7	10	0.24	5.6	9.0	12	19
Adolescents (≥ 10 to < 18 years)	0.05	1.1	1.8	2.5	3.8	0.12	2.9	4.6	6.1	9.6
Adults (≥ 18 to < 65 years)	0.02	0.57	0.92	1.2	1.9	0.06	1.4	2.3	3.0	4.7
Elderly (≥ 65 to < 75 years)	0.02	0.49	0.79	1.0	1.6	0.05	1.1	1.8	2.4	3.7
Very elderly (≥ 75 years)	0.02	0.51	0.82	1.1	1.7	0.05	1.1	1.7	2.3	3.6
Pregnant women	0.02	0.57	0.92	1.2	1.9	0.06	1.3	2.1	2.8	4.4
Lactating women	0.03	0.59	0.95	1.3	2.0	0.05	1.3	2.1	2.7	4.3

Exposure of average and high milk and dairy products consumers with Δ^9 -THC and comparison with the ARfD. For the calculation of the different exposure scenarios, the EFSA RACE tool was used. The RACE tool estimates acute and chronic exposure from single foods using food consumption information from the EFSA Comprehensive European Food Consumption Database (Comprehensive Database), comparing it to relevant toxicological reference points. The Comprehensive Database summarizes existing national information on food consumption at the individual level and is the most complete and detailed collection of food consumption data currently available for the European Union. Mean and maximum Δ^9 -THC values in milk during adaptation (day 14) and exposure period (day 16–20) of the feeding experiment and an ARfD of $1 \mu\text{g } \Delta^9\text{-THC per kg body weight}$ were taken as a basis. Similar to previous exposure estimates⁶, it was assumed that this concentration would be found in milk and milk products made thereof. Bold numbers indicate values in excess of the ARfD (1=100%).

be completely ruled out. The HPLC–MS/MS-based analysis method we developed enables a precise determination of the cannabinoid concentration, and differentiates between psychoactive Δ^9 -THC and non-psychoactive Δ^9 -THCA. The toxicokinetic modelling has shown that the transfer rates of the examined cannabinoids from feed to milk were less than 1%. Nevertheless, due to the high feed intake, cow's milk reached substantial levels of Δ^9 -THC such that the exposure might exceed ARfD in some population groups in our exposure scenario based on the transfer properties presented here. For other cannabinoids, in particular for CBD, which was present in high amounts in industrial hemp (and thus also in cow's milk after feeding), the data are currently insufficient, thereby preventing an assessment of possible health risks.

Methods

Feeding experiment

A feeding experiment was conducted with ten lactating Holstein Friesian dairy cows at the German Federal Institute for Risk Assessment (BfR). The experiment was performed in accordance with relevant guidelines and regulations and was approved by the Regional Office for Health and Social Affairs Berlin (LAGeSo, approval number G 0239/17). For detailed data on the animals at the beginning of the experiment, see Supplementary Table 9.

The animals were divided in two groups (L, low hemp; H, high hemp) and housed in cubicles. A partially mixed ration (PMR) was administered in feeding troughs with transponder-controlled scales allowing recording of individual feed intake. The experiment was divided into four periods: control (7 d), adaptation (7 d), exposure (6 d) and depuration (8 d). In the control period, both groups received a hemp-free PMR, containing 7.56 kg corn silage, 1.03 kg wheat straw, 0.87 kg hay, 1.17 kg fodder beet, 3.60 kg rapeseed meal and 0.88 kg of a supplementary feed rich in vitamins and minerals per cow and day (all data in DM). The PMR covered a milk yield of 15 litres per cow per day. In addition, concentrate was provided through transponder-controlled automated feeders based on individual milk yield (0.5 kg per additional litre of milk yield; maximum 5 kg of concentrate per day). Water was offered ad libitum. In the adaptation period, part of the corn silage was gradually replaced with industrial hemp silage A (0.31–0.92 kg DM

per cow), containing cannabinoids at very low concentrations. In the exposure period, groups L and H had the corn silage replaced proportionately with 0.84 and 1.68 kg DM per cow, respectively, of industrial hemp silage E with higher cannabinoid concentration. Different dosages were chosen to determine dose-dependent effects on the transfer of cannabinoids into milk, cow's performance and health status. In the depuration period, both groups were again fed with hemp-free diets. Energy content of the PMR was 6.4–6.6 MJ net energy for lactation per kg DM, depending on the experimental period. For more information on the composition of the diets, see Supplementary Table 1. Throughout the experiment, animal health parameters and performance (feed intake, milk yield, respiratory rate, heart rate and body temperature) were recorded daily, as were behavioural observations. For this the animals were observed for conspicuous behaviour compared to the control period. The focus was on the parameters 'muscle tremors', 'hypersalivation' and 'disturbed movement coordination' described in the literature. Since only an initial recording of possible effects was intended, the observations were not standardized using an ethogram. The respiratory rate of all animals was determined by counting the respiratory movements of the flank region and expressed as breaths per minute. The heart rate was determined by auscultating the chest wall with a stethoscope and expressed as beats per minute. The body temperature was measured rectally. Animal weight was measured weekly using floor scales. Milk samples were collected for each cow twice a day, while blood and faeces were taken only from two cows per group and on few, selected days.

Two different industrial hemp varieties were used for the experiment. The industrial hemp variety 'Ivory' was selected as a representative of particularly low Δ^9 -THC varieties for the adaptation period of the experiment; the industrial hemp variety 'Finola' was selected as a representative of varieties with rather higher Δ^9 -THC concentration (but still below 0.2% total Δ^9 -THC) for the exposure period. Both varieties were cultivated at the Leibniz Institute for Agricultural Engineering and Bioeconomy Potsdam (ATB), Germany, in spring 2016. The harvest of the hemp took place at the end of August 2016, at which time the 'Ivory' variety was in the seed formation stage. The 'Finola' variety already bore the first fully mature seeds. The 'Ivory' variety was cut with a harvester

(JF FC 800) and the entire plant was chopped to produce whole plant silage (silage A). For the production of a leaf-flower-seed silage (silage E), only leaves, flowers and seeds of the 'Finola' variety were harvested. For this purpose, a home-made harvester, constructed by the ATB, was used, which removed the desired plant parts from the stem by means of whips. Immediately after harvest, the hemp was moved into round 510 litre rain barrels, compacted in layers by body weight (tamping) and then sealed airtight. A water-filled hose in the barrel lid allowed gas to escape from the ensiled material without allowing ambient air to flow in. No silage additives were added. In October 2017, the industrial hemp silages were opened, aliquoted in 120 litre bags and stored at -20°C for the experiment. The cannabinoid concentration of the industrial hemp silages can be found in Table 1.

Sampling

Milk samples for cannabinoid analysis were taken at days 7, 14–24, 26 and 28. The cows were milked in a double tandem milking parlour until the milk flow stopped and the milk was collected in milking pails. Before sampling, milk was stirred to achieve an even distribution of the lipophilic cannabinoids. The resulting milk samples were refrigerated (8°C) for a maximum of 18 h until mixing. After reheating (37°C , water bath), samples of evening and the following morning milk of each cow were mixed according to their proportion of daily production. The resulting composite samples were stored in lightproof high-density polyethylene bottles and were frozen at -20°C until analysis. Milk samples for the determination of milk constituents were taken at the end of each period and were refrigerated at 8°C until analysis.

Blood plasma and faeces were collected from two animals per group at days 7, 14, 20 and 22. Blood was obtained by puncturing the jugular vein and collected in coagulant tubes with potassium oxalate monohydrate. After cooling for 30 min, blood samples were centrifuged at $1,876g$ for 15 min and the plasma extracted and stored for analysis. Blood plasma was used instead of whole blood because of ease of handling and because plasma has been shown to contain a large proportion of blood cannabinoids^{36–38}. Faeces was collected during spontaneous defecation, when possible. Otherwise, faeces was collected from the rectum. Plasma and faeces samples for the determination of cannabinoids were stored in lightproof high-density polyethylene bottles and were frozen at -20°C until analysis. Samples of the hemp silage were taken prior to the experiment and were stored in freezer bags at -20°C until analysis.

Cannabinoid analysis

The cannabinoid analysis was performed at the Chemical and Veterinary Analytical Institute Münsterland-Emscher-Lippe (CVUA-MEL), according to an approach described in ref.³⁹. The method comprises the following native cannabinoids: Δ^9 -THC, Δ^9 -THCA, Δ^8 -THC, Δ^9 -THCV, CBD, CBN, CBDV, and the two Δ^9 -THC-metabolites 11-OH-THC and THC-COOH. For calculation of the recoveries and quantification, the following deuterated internal standards were used: Δ^9 -THC- D_3 , CBD- D_3 , CBN- D_3 , 11-OH- Δ^9 -THC- D_3 , 11-nor-9-carboxy- Δ^9 -THC- D_3 and 11-nor-9-carboxy- Δ^9 -THC- D_6 . Except for Δ^9 -THCA, which was purchased from Fluka, all other compounds were acquired from Cerilliant.

At the beginning of the analysis, the samples were fortified with a mixture of deuterated internal standards. A further deuterated standard was added at the end of the clean-up prior to the analytical determination. The extraction and the subsequent clean-up steps were adapted to the various matrices and differ to some extent. The final analytical separation, identification and quantification by HPLC–MS/MS were the same for all matrices.

Milk extraction and clean-up. The extraction of cannabinoids from milk was performed with acetone in a polypropylene tube by shaking on an orbital shaker. Precipitated proteins and sugars were removed after centrifugation. A subsequent liquid/liquid extraction with hexane

in the presence of a saturated NaCl solution followed. After phase separation, the organic phase was subsequently evaporated to dryness under a gentle stream of nitrogen. Following reconstitution with cyclohexane/ethyl acetate (1 + 1), application of gel permeation chromatography (GPC) on Bio-Beads S-X3 served as the final clean-up step. After GPC clean-up, ethylenglycol was added to the extract which after careful evaporation was reconstituted in acetonitrile/water (50/50) for HPLC–MS/MS analysis.

Plasma extraction and clean-up. Plasma samples were subjected to an enzymatic cleavage with β -glucuronidase in phosphate buffer for 3 h at 50°C . After cooling down, acetic acid and acetone were added to the solution for the extraction of the cannabinoids, which was performed by shaking on an orbital shaker. Plasma samples without cleavage were extracted with acetic acid and acetone by shaking on an orbital shaker. After centrifugation and removal of precipitated coextractives, a liquid/liquid extraction with hexane in the presence of a saturated Na_2SO_4 solution was performed. Ethylenglycol was added to the organic phase, which was carefully evaporated to dryness and subsequently reconstituted in acetonitrile/water (50/50) for HPLC–MS/MS analysis. Due to unexplained losses of Δ^9 -THC and other cannabinoids during β -glucuronidase treatment, we decided to use the analysis values without enzymatic cleavage for evaluation and modelling.

Feed and faeces extraction and clean-up. Feed and faeces samples were mixed with Na_2SO_4 , transferred into an extraction thimble and extracted with acetone for 6–8 h in a Soxhlet apparatus. The extract was reduced and, depending on the concentrations of the cannabinoids, an aliquot of the concentrated extract was evaporated under a gentle stream of nitrogen to dryness. After reconstitution in cyclohexane/ethyl acetate (1 + 1), the extract was further purified on GPC as described for milk.

HPLC–MS/MS analysis. HPLC–MS/MS analysis was performed on an Agilent 6460A triple-quadrupole system equipped with an electrospray source operated in positive ionization mode. For separation of the analytes, a ZorBAX SB-C18 column (2.1×10 mm, $1.8 \mu\text{m}$) at a column temperature of 30°C was used. A flow rate of 0.2 ml min^{-1} and a gradient comprising of acetonitrile/0.1% formic acid (eluent A) and water/0.1% formic acid (eluent B) were applied.

For each cannabinoid and metabolite the collision energies in MS/MS mode were optimized to gain at least two intensive transitions. While the first transition was used for quantification based on a seven-point calibration curve, the second transition served as a qualifier; that is, the ratio of the two transitions had to comply with the corresponding reference standard as a second criterion besides the complying retention time for unequivocal identification of the respective analyte.

Depending on the cannabinoid and metabolite, the limits of detection (LOD) were determined as 0.01 – 0.4 ng ml^{-1} for milk, 0.1 – 0.5 ng ml^{-1} for plasma and 0.2 – 2.0 ng per g DM for feed and faeces. The corresponding limits of quantification (LOQ) were a factor of three higher.

The validation of the accredited method was performed by spiking experiments of cannabinoid-free matrices at a high and a low level, respectively, which generally revealed recoveries of $>85\%$ and coefficients of variation of $<15\%$.

Analysis of milk constituents

The fat, protein, lactose and DM content of milk were analysed using accredited methods. Urea was measured using a Reflotron; somatic cell count was performed using a DeLaval DCC. All analyses were conducted at the BfR. The daily values of each parameter were calculated from the received values of the evening and the following morning milk samples.

Statistics

One animal from group L was excluded from the experiment at the beginning of the adaptation period due to a disease not related to

the experiment (lameness). One animal from group H completed the experiment and was subsequently excluded from the statistical calculations due to a metabolic disease (subclinical ketosis) developed during the experiment. The statistical evaluation was conducted with the data from the remaining eight animals. Since our data did not follow a normal distribution, non-parametric tests were used.

Animal health parameters and performance—feed intake, milk yield, respiratory rate, heart rate, body temperature, body weight and milk constituents—were compared between six groups (1, groups L + H: control; 2, groups L + H: adaptation; 3, group L: exposure; 4, group H: exposure; 5, group L: depuration; 6, group H: depuration) applying the non-parametric Kruskal–Wallis test with the function `kruskal.test()` from the `stats` package. Post hoc analyses were performed with the non-parametric Tukey test (pairwise comparisons) with the `glht` function from the R package `multcomp`⁴⁰ to find the groups that differ significantly after global the Kruskal–Wallis test rejected the null hypothesis.

To show the distribution of animal health parameters and performance in groups and periods, a violin plot combines the kernel density curve with an error bar⁴¹. The error shows the mean and the standard deviation. Different letters on plots indicate statistical significance in pairwise comparisons performed with Tukey post hoc tests. Letters shared in common between six groups (15 pairwise tests) indicate no significant difference. Statistical evaluations and graphs were performed with the statistical software R v.4.0.2⁴². All statistical tests were two-sided.

Modelling

Data processing. As experimental data were available in concentrations and we opted for modelling cannabinoid amounts, we calculated cannabinoid amounts from the experimental data. To do so, we used both experimental data (that is, daily milk yield, body weight) and equations from veterinary literature to infer the missing information. To obtain the daily cannabinoid amount in milk $A_{\text{milk,daily}}$, the daily milk yield is multiplied with the cannabinoid concentration on each day. We assume each cow to have 65 ml blood per kg body weight (physiological range, 55–75 ml per kg body weight⁴³) and a haematocrit of 33.8% (physiological range, 19.5–42.5%⁴⁴), so that each cow has 43 ml plasma per kg body weight. The daily dry faecal output $M_{\text{faeces,daily}}$ was estimated using the mass balance, where

$$M_{\text{faeces,daily}} = \frac{1 - dDM}{0.10} \times M_{\text{feed}} \quad (1)$$

with digestible dry matter $dDM = 79.36 - 2.85NL$, where NL is the nutrition level of the cow, calculated from the cow's daily feed uptake⁴⁵. For concentration values under the LOD or LOQ, we set them to the respective LOD/LOQ value (upper bound estimation). For intake data at time t , $I(t)$, we multiplied the feed intake amount with the cannabinoid concentration. Since there were problems with the urine analysis, we could not use the urinary concentration data.

Mathematical models. After analysing different options, we opted for a two-compartment model (Fig. 3a), which provides an accurate mathematical representation of the observed data, compatible with the limitations of the available dataset. We used two different versions of it, model A for Δ^9 -THC and CBD for which some plasma concentration data are available, and model B for the remaining cannabinoids (Δ^9 -THCA, Δ^9 -THCV, CBN and CBDV), for which plasma levels were not consistently detectable.

Model A has two compartments, GI (gastrointestinal) tract and plasma. The GI tract compartment takes the daily amount of cannabinoid ingested by the cow as input $I(t)$, transfers the absorbed cannabinoid amount into the plasma and outputs the amount of cannabinoid excreted with faeces out of the system. The parameters regulating this process are F_a (fraction absorbed) and k_p , the latter regulating the rate

of passage out of the GI tract, which contains an A_{GItract} amount of cannabinoids. We fixed k_p at 1.3 d^{-1} , a value tantamount to a GI tract passage rate of $5\% \text{ h}^{-1}$, in accordance with animal physiology literature⁴⁶. The plasma compartment, which takes its input from the GI tract, outputs either to milk (A_{milk} , mainly controlled by parameter k_m) or to elimination (through parameter k_e). The latter is mainly controlling the total amount of cannabinoids eliminated A_{elim} (lumping putative urinary excretion, metabolization and other possible physiological processes). The mathematical representation of the model is a system of ordinary differential equations that assumes zero- or first-order kinetics for all of the modelled processes, so that

$$\frac{dA_{\text{milk}}}{dt} = A_{\text{plasma}} \times k_m \quad (2)$$

$$\frac{dA_{\text{plasma}}}{dt} = A_{\text{GItract}} F_a k_p - A_{\text{plasma}} \times k_m - A_{\text{plasma}} \times k_e \quad (3)$$

$$\frac{dA_{\text{faeces}}}{dt} = A_{\text{GItract}} \times (1 - F_a) \times k_p \quad (4)$$

$$\frac{dA_{\text{elim}}}{dt} = A_{\text{plasma}} \times k_e \quad (5)$$

$$\begin{aligned} \frac{dA_{\text{GItract}}}{dt} &= I(t) - k_p \times F_a \times A_{\text{GItract}} - (1 - F_a) \times k_p \times A_{\text{GItract}} \\ &= I(t) - k_p \times A_{\text{GItract}} \end{aligned} \quad (6)$$

The amount of cannabinoid transferred into milk is then given by

$$A_{\text{milk}} = \int_0^t A_{\text{plasma}}(t) \times k_m dt \quad (7)$$

$$A_{\text{milk,daily}} = A_{\text{milk,day}_i} - A_{\text{milk,day}_{i-1}} \quad (8)$$

For the complete equation set, see the description of model A in the Supplementary Information.

Model B is a simplification of model A, where the plasma becomes a central compartment with only one output to milk. In this case, the absorption parameter becomes F_b , that is, the absorbed fraction bioavailable for milk excretion. The GI tract output becomes the total elimination, accounting not only for faecal excretion but also for putative physiological elimination processes such as urinary excretion, metabolization and other possible processes. The ordinary differential equation system in this case becomes

$$\frac{dA_{\text{milk}}}{dt} = A_{\text{central}} \times k_m \quad (9)$$

$$\frac{dA_{\text{central}}}{dt} = A_{\text{GItract}} \times F_b \times k_p - A_{\text{central}} \times k_m \quad (10)$$

$$\frac{dA_{\text{elim,tot}}}{dt} = A_{\text{GItract}} \times (1 - F_b) \times k_p \quad (11)$$

$$\frac{dA_{\text{GItract}}}{dt} = I(t) - k_p \times A_{\text{GItract}} \quad (12)$$

The amount of cannabinoid transferred into milk is

$$A_{\text{milk}} = \int_0^t A_{\text{central}}(t) \times k_m dt \quad (13)$$

The complete equation set can be found in the description of model B in the Supplementary Information.

Obtaining optimized model parameters. The models were implemented using Python3 and then fitted with the `lmfit` module to the data to obtain parameters for the predictive model. The `lmfit` module (<https://lmfit.github.io/lmfit-py/>) provides a solid interface to perform nonlinear least-squares minimization. The code is available in the Supplementary Information, as is an executable Python file with the predictive model (`PredictiveModel.zip`). We used the Levenberg–Marquardt algorithm to solve the minimization problem, with the distance function being the squared difference between the dataset points (amount of cannabinoid excreted with milk/faeces or present in milk on a given day) and the corresponding modelled amount. For each cannabinoid, we fitted one model to each cow dataset, obtaining a range of parameter estimates (Supplementary Fig. 2). Cow H5 model was not included in the final average parameters estimation because of the subclinical ketosis it developed during the experiment. As the available data (non-milk data were available only for two cows in each group) were not sufficient for the solver to find a minimum for the objective function (squared sum of residuals), we placed a boundary on the parameter space. To obtain the final parameter estimation, we used the following procedure:

Model A:

1. Fix $k_p = 1.3 \text{ d}^{-1}$.
2. Fit model to each single cow dataset (initial estimate: $F_a = 0.8$, $k_m = 10$, $k_e = 3,000$).
3. Calculate \bar{F}_a using only F_a from models fitted to dataset with non-milk data.
4. Set $F_a = \bar{F}_a$ for next fit initial estimate.
5. Set F_a not to vary in fit for cows without non-milk data.
6. Fit each single cow dataset to model A with updated initial estimate.
7. Calculate \bar{k}_e (geometric mean).
8. Set upper bound for $k_e = \bar{k}_e$.
9. Fit model to each single cow dataset with updated constraints
10. Take the average of each parameter (using the geometric mean where appropriate), excluding cow H5 (subclinical ketosis), as the final model parameters.

Model B:

1. Fix $k_p = 1.3 \text{ d}^{-1}$.
2. Fix $k_m = 1 \text{ d}^{-1}$.
3. Fit each single cow dataset milk data to model B to obtain F_b (initial estimate: $F_b = 0.01$).
4. Final model parameter is $F_b = \bar{F}_b$ (arithmetic average excluding cow H5, subclinical ketosis)

Predictive model. The optimized model parameters were used to create a predictive cannabinoid milk transfer model for each of the selected cannabinoids. Two Python files, containing an implementation of the model, are included in the Supplementary Software (`PredictiveModel.zip`). To run the model, open the `exec.py` file in a Python3 console, select a cannabinoid by assigning to the `CANNABINOID` variable the correct string, set the `DOSE`, `EXPOSURE_DURATION` and `DEPU-RATION` values and run the code. It will return a plot with the selected cannabinoid amount in milk over the selected exposure scenario.

Assessment of consumer exposure to Δ^9 -THC using the RACE tool

To evaluate the concentration of Δ^9 -THC we measured in cow milk, the EFSA RACE software tool was used. The RACE tool estimates acute and chronic exposure from single foods using food consumption

information from the EFSA Comprehensive European Food Consumption Database (Comprehensive Database), comparing it to relevant toxicological reference points. The Comprehensive Database summarizes existing national information on food consumption at the individual level and is the most complete and detailed collection of food consumption data currently available for the European Union. Among other things, the output of the tool is the percentage exhaustion of the toxicological reference value for various population groups³⁵. For the assessment, the mean and maximum Δ^9 -THC concentrations in milk during the adaptation and exposure period were used. Analogous to previous exposure estimates⁶, it was assumed that this concentration would be found in milk and milk products made from it. Due to the delayed build-up of Δ^9 -THC in milk, the values of the last day of the adaptation period and the second to sixth day of the exposure period were used to calculate the means. The ARfD of 1 μg per kg body weight derived by the EFSA⁶ was applied as the toxicological reference value.

Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

Data availability

The datasets generated during the experiment are available from the corresponding authors on reasonable request.

Code availability

The complete code for modelling is available from the corresponding authors on reasonable request.

References

1. Crini, G., Lichtfouse, E., Chanut, G. & Morin-Crini, N. Applications of hemp in textiles, paper industry, insulation and building materials, horticulture, animal nutrition, food and beverages, nutraceuticals, cosmetics and hygiene, medicine, agrochemistry, energy production and environment: a review. *Environ. Chem. Lett.* **18**, 1451–1476 (2020).
2. Karche, T. The application of hemp (*Cannabis sativa* L.) for a green economy: a review. *Turk. J. Bot.* **43**, 710–723 (2019).
3. Pertwee, R. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ^9 -tetrahydrocannabinol, cannabidiol and Δ^9 -tetrahydrocannabivarin. *Br. J. Pharmacol.* **153**, 199–215 (2008).
4. European Union. L181. *Official Journal of the European Union* **57**, 1–81 <https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=OJ:L:2014:181:TOC> (2014).
5. European Union. L435. *Official Journal of the European Union* **64**, 1–314 <https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=OJ:L:2021:435:TOC> (2021).
6. EFSA, European Food Safety Agency, Panel on Contaminants in the Food Chain. Scientific opinion on the risks for human health related to the presence of tetrahydrocannabinol (THC) in milk and other food of animal origin. *EFSA J.* **13**, 4141 (2015).
7. Doorenbos, N. J., Fetterman, P. S., Quimby, M. W. & Turner, C. E. Cultivation, extraction, and analysis of *Cannabis sativa* L. *Ann. NY Acad. Sci.* **191**, 3–14 (1971).
8. Kleinhenz, M. D. et al. Plasma concentrations of eleven cannabinoids in cattle following oral administration of industrial hemp (*Cannabis sativa*). *Sci. Rep.* **10**, 1–7 (2020).
9. Farrimond, J. A., Hill, A. J., Whalley, B. J. & Williams, C. M. Cannabis constituents modulate Δ^9 -tetrahydrocannabinol-induced hyperphagia in rats. *Psychopharmacology* **210**, 97–106 (2010).
10. Farrimond, J. A., Whalley, B. J. & Williams, C. M. Cannabinol and cannabidiol exert opposing effects on rat feeding patterns. *Psychopharmacology* **223**, 117–129 (2012).

11. Wiley, J. L. et al. CB1 cannabinoid receptor-mediated modulation of food intake in mice. *Br. J. Pharmacol.* **145**, 293–300 (2005).
12. Thompson, G. R., Mason, M. M., Rosenkrantz, H. & Braude, M. C. Chronic oral toxicity of cannabinoids in rats. *Toxicol. Appl. Pharmacol.* **25**, 373–390 (1973).
13. Thompson, G. R., Rosenkrantz, H., Schaeppi, U. H. & Braude, M. C. Comparison of acute oral toxicity of cannabinoids in rats, dogs and monkeys. *Toxicol. Appl. Pharmacol.* **25**, 363–372 (1973).
14. Wu, Z. & Huber, J. Relationship between dietary fat supplementation and milk protein concentration in lactating cows: a review. *Livest. Prod. Sci.* **39**, 141–155 (1994).
15. Kleinhenz, M. D. et al. Nutrient concentrations, digestibility, and cannabinoid concentrations of industrial hemp plant components. *Appl. Anim. Sci.* **36**, 489–494 (2020).
16. Riedel, G. et al. Synthetic and plant-derived cannabinoid receptor antagonists show hypophagic properties in fasted and non-fasted mice. *Br. J. Pharmacol.* **156**, 1154–1166 (2009).
17. Fernandes, M., Schabarek, A., Coper, H. & Hill, R. Modification of Δ^9 -THC-actions by cannabidiol and cannabidiol in the rat. *Psychopharmacologia* **38**, 329–338 (1974).
18. Pace, H. B., Davis, W. M. & Borgen, L. A. Teratogenesis and marijuana. *Ann. NY Acad. Sci.* **191**, 123–131 (1971).
19. Bergamaschi, M. M., Queiroz, R. H. C., Zuardi, A. W. & Crippa, A. S. Safety and side effects of cannabidiol, a *Cannabis sativa* constituent. *Curr. Drug Saf.* **6**, 237–249 (2011).
20. Moss, I. R. & Friedman, E. Δ^9 -Tetrahydrocannabinol: depression of ventilatory regulation; other respiratory and cardiovascular effects. *Life Sci.* **19**, 99–104 (1976).
21. Graham, J. & Li, D. Cardiovascular and respiratory effects of cannabis in cat and rat. *Br. J. Pharmacol.* **49**, 1–10 (1973).
22. Ménétrey, A. et al. Assessment of driving capability through the use of clinical and psychomotor tests in relation to blood cannabinoid levels following oral administration of 20 mg dronabinol or of a cannabis decoction made with 20 or 60 mg Δ^9 -THC. *J. Anal. Toxicol.* **29**, 327–338 (2005).
23. Clark, S. Marijuana and the cardiovascular system. *Pharmacol. Biochem. Behav.* **3**, 299–306 (1975).
24. Solowij, N. et al. A randomised controlled trial of vaporised Δ^9 -tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: acute intoxication effects. *Eur. Arch. Psychiat. Clin. Neurosci.* **269**, 17–35 (2019).
25. McPartland, J. M., Duncan, M., Di Marzo, V. & Pertwee, R. G. Are cannabidiol and Δ^9 -tetrahydrocannabinol negative modulators of the endocannabinoid system? A systematic review. *Br. J. Pharmacol.* **172**, 737–753 (2015).
26. Russo, E. B. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. *Br. J. Pharmacol.* **163**, 1344–1364 (2011).
27. Della Rocca, G. & Di Salvo, A. Hemp in veterinary medicine: from feed to drug. *Front. Vet. Sci.* **7**, 387 (2020).
28. Burgel, L., Hartung, J., Pflugfelder, A. & Graeff-Hönninger, S. Impact of growth stage and biomass fractions on cannabinoid content and yield of different hemp (*Cannabis sativa* L.) genotypes. *Agronomy* **10**, 372 (2020).
29. Guidon, D. & Zoller, O. Übergang von THC in die Kuhmilch. *Mitt. Lebensmittelunters. Hyg.* **90**, 373 (1999).
30. Ahmad, G. R. & Ahmad, N. Passive consumption of marijuana through milk: a low level chronic exposure to delta-9-tetrahydrocannabinol (THC). *J. Toxicol. Clin. Toxicol.* **28**, 255–260 (1990).
31. Moss, M. J. et al. Cannabis use and measurement of cannabinoids in plasma and breast milk of breastfeeding mothers. *Pediatr. Res.* **90**, 861–868 (2021).
32. Baker, T. et al. Transfer of inhaled cannabis into human breast milk. *Obstet. Gynecol.* **131**, 783–788 (2018).
33. Sempio, C. et al. Detection of cannabinoids by LC-MS-MS and ELISA in breast milk. *J. Anal. Toxicol.* **45**, 686–692 (2021).
34. Golombek, P., Müller, M., Barthlott, I., Sproll, C. & Lachenmeier, D. W. Conversion of cannabidiol (CBD) into psychotropic cannabinoids including tetrahydrocannabinol (THC): a controversy in the scientific literature. *Toxics* **8**, 41 (2020).
35. *Risk Evaluation of Chemical Contaminants in Food in the context of RASFF Notifications: Rapid Assessment of Contaminant Exposure Tool (RACE)*. EFSA Supporting Publication 2019:EN-1625 (European Food Safety Agency, 2019).
36. Fehr, K. O. & Kalant, H. Fate of ^{14}C - Δ^1 -THC in rat plasma after intravenous injection and smoking. *Eur. J. Pharmacol.* **25**, 1–8 (1974).
37. Widman, M., Agurell, S., Ehrnebo, M. & Jones, G. Binding of (+)- and (-)- Δ^1 -tetrahydrocannabinols and (-)-7-hydroxy- Δ^1 -tetrahydrocannabinol to blood cells and plasma proteins in man. *J. Pharm. Pharmacol.* **26**, 914–916 (1974).
38. Wahlqvist, M., Nilsson, I., Sandberg, F., Agurell, S. & Granstrand, B. Binding of δ^1 -tetrahydrocannabinol to human plasma proteins. *Biochem. Pharmacol.* **19**, 2579–2582 (1970).
39. Meyer, C. *Bestimmung von THC und weiteren Cannabinoiden in Lebensmitteln und Futtermitteln*. Master's thesis, Univ. Münster (2016).
40. Hothorn, T., Bretz, F. & Westfall, P. Simultaneous inference in general parametric models. *Biom. J.* **50**, 346–363 (2008).
41. Wickham, H. *ggplot2: Elegant Graphics for Data Analysis* 1st edn (Springer, 2009).
42. *R: A Language and Environment for Statistical Computing* (R Foundation for Statistical Computing, 2021).
43. von Engelhardt, W., Breves, G., Diener, M. & Gäbel, G. *Physiologie der Haustiere* (Georg Thieme, 2015).
44. Lane, A. & Campbell, J. Relationship of hematocrit values to selected physiological conditions in dairy cattle. *J. Anim. Sci.* **28**, 508–511 (1969).
45. Gabel, M. et al. Influence of nutrition level on digestibility in high yielding cows and effects on energy evaluation systems. *J. Dairy Sci.* **86**, 3992–3998 (2003).
46. Krizsan, S., Ahvenjärvi, S. & Huhtanen, P. A meta-analysis of passage rate estimated by rumen evacuation with cattle and evaluation of passage rate prediction models. *J. Dairy Sci.* **93**, 5890–5901 (2010).

Acknowledgements

We are grateful to H. J. Gusovius and C. Idler (Leibniz Institute for Agricultural Engineering and Bioeconomy, Potsdam) for their assistance in the production and nutritional analysis of the two hemp silages. We would like to acknowledge the assistance of M. Hellwig, H.-M. Lochotzke, U. Götte and animal caretakers at the BfR during the animal experiment. This study was financially supported by institutional funding through BfR-SiN-08-1322-635.

Author contributions

B.W. planned and carried out the animal experiment. P.G. and J.N. developed the toxicokinetic model. P.F., T.B. and O.K. developed the new analysis method and analysed the samples. A.M. carried out the statistical analysis. B.S. was responsible for the risk characterization of cannabinoids in food. M.C.L. carried out the RACE tool calculations. R.P. supervised the evaluation of the data. All authors contributed to writing and revising the manuscript.

Competing interests

The authors declare no competing interests.

Additional information

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s43016-022-00623-7>.

Correspondence and requests for materials should be addressed to Bettina Wagner or Robert Pieper.

Peer review information *Nature Food* thanks Patrick Gorden, Michael Kleinhenz and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2022

Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

- | | | |
|-------------------------------------|-------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <input type="checkbox"/> | <input checked="" type="checkbox"/> | The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> | A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> | The statistical test(s) used AND whether they are one- or two-sided
<i>Only common tests should be described solely by name; describe more complex techniques in the Methods section.</i> |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> | A description of all covariates tested |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> | A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> | A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> | For null hypothesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted
<i>Give P values as exact values whenever suitable.</i> |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> | For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> | For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> | Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated |

Our web collection on [statistics for biologists](#) contains articles on many of the points above.

Software and code

Policy information about [availability of computer code](#)

Data collection

Data analysis

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research [guidelines for submitting code & software](#) for further information.

Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	<p>The sample size was determined using, among other things, the mean $\Delta 9$-THC concentration in milk and the known exposure to $\Delta 9$-THC from a previous in-house pilot study. The experiment presented in this manuscript was designed to provide an estimator for the mean (μ) of the main target variable, the $\Delta 9$-THC concentration in cow's milk, with a confidence interval D. The number of animals was determined based on the specified tolerable confidence interval D [1,2]. The confidence interval was chosen using consumer protection considerations, such that the widest possible confidence interval $D_{\text{GroupL}}=0.085$ mg/L and $D_{\text{GroupH}}=0.170$ mg/L for $\Delta 9$-THC. These confidence intervals ensure the usefulness of the experimental results for the assessment of consumer risk resulting from the ingestion of $\Delta 9$-THC with cow's milk.</p> <p>The coefficient of variation σ/μ of the main target variable is also needed for the calculation. Since σ/μ is not known, it is estimated using data from a comparable substance, cypermethrin, from a similar study with dairy cows [3]. The number of animals is then calculated as $n_{\text{(GroupsL+H)}} \geq t^2(1-\alpha/2, n-1)/(D/\sigma)^2$ where t is Student's t distribution. The result is $n_{\text{(GroupsL+H)}} \geq 9$ for both groups taken together.</p> <p>[1] Glaser S, Kreienbrock L. Stichprobenplanung bei veterinärmedizinischen Studien. Ein Leitfaden zur Bestimmung des Untersuchungsumfanges. Hannover: Schlütersche; 2011. [2] Sachs, L., Hedderich, J. (2006) Angewandte Statistik – Methodensammlung mit R, Springer, Heidelberg. (Abschnitt 6.6.2, Konfidenzintervall für den Erwartungswert μ) [3] A. W. Chen, J. M. Fink, D.J. Letinski, G. P. Barrett, J.C. Pearsall, Residue of Cypermethrin and Its Major Acid Metabolites in Milk and Tissues from Dairy Bovines Treated with Cypermethrin, J. Agric. Food Chem. 1997.</p>
Data exclusions	<p>One animal from group L was excluded from the experiment at the beginning of the adaptation period due to a disease not related to the experiment (lameness). One animal from group H completed the experiment and was subsequently excluded from the statistical calculations due to a metabolic disease (subclinical ketosis) developed during the experiment. This was not pre-established. The statistical evaluation was conducted with the data from the remaining eight animals. Despite the lower power in the statistical tests (8 animals instead of 9), the p-values showed a clear trend.</p>
Replication	<p>All attempts at replication were successful.</p>
Randomization	<p>The assignment to the two test groups was carried out randomly by drawing lots.</p>
Blinding	<p>Both test groups first went through a control phase and then received the cannabinoid-containing test ration in different dosages. Due to the necessary veterinary monitoring of the two test groups, there was no blinding at the stable level in order to be able to react with a dose reduction if necessary. The milk samples were sent to the laboratory in a blinded manner, so that the samples were analyzed without knowledge of the group assignment or experimental phase.</p>

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

n/a	Included in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/> Antibodies
<input checked="" type="checkbox"/>	<input type="checkbox"/> Eukaryotic cell lines
<input checked="" type="checkbox"/>	<input type="checkbox"/> Palaeontology and archaeology
<input type="checkbox"/>	<input checked="" type="checkbox"/> Animals and other organisms
<input checked="" type="checkbox"/>	<input type="checkbox"/> Human research participants
<input checked="" type="checkbox"/>	<input type="checkbox"/> Clinical data
<input checked="" type="checkbox"/>	<input type="checkbox"/> Dual use research of concern

Methods

n/a	Included in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/> ChIP-seq
<input checked="" type="checkbox"/>	<input type="checkbox"/> Flow cytometry
<input checked="" type="checkbox"/>	<input type="checkbox"/> MRI-based neuroimaging

Animals and other organisms

Policy information about [studies involving animals](#); [ARRIVE guidelines](#) recommended for reporting animal research

Laboratory animals	The study did not involve laboratory animals (rather farm animals in controlled barn conditions).
Wild animals	The study did not involve wild animals.
Field-collected samples	<p>The feeding experiment was conducted with ten lactating Holstein Frisian dairy cows at the German Federal Institute for Risk Assessment (BfR). The husbandry of the dairy cows at the BfR corresponds to conventional large animal husbandry under agricultural conditions and takes place in freestall barns. The lying areas are equipped with rubber mats. Faeces and urine are removed by automatic manure scrapers. The barn is illuminated by daylight through barn windows and fluorescent tubes. The requirements of Section 2 of the German Animal Welfare Act and the Animal Welfare Guidelines for Dairy Cattle Husbandry [4] are met. The barn is not heated. The experiment took place in late autumn.</p> <p>A partially mixed ration (PMR) was administered in feeding troughs with transponder-controlled scales allowing recording of individual feed intake. Both groups received a hemp-free PMR, containing 7.56 kg corn silage, 1.03 kg wheat straw, 0.87 kg hay, 1.17 kg fodder beet, 3.60 kg rapeseed meal and 0.88 kg of a supplementary feed rich in vitamins and minerals per cow and day (all data in dry matter, DM). The PMR covered a milk yield of 15 litres/cow/day. In addition, concentrate was provided through transponder-controlled automated feeders based on individual milk yield (0.5 kg per additional litre of milk yield, maximum 5 kg of concentrate per day). Water was offered ad libitum. During two experimental periods part of the corn silage was gradually replaced with industrial hemp silage.</p> <p>The cows were milked twice a day.</p> <p>The cows were not inseminated before the experiment, so only non-gestating dairy cows were used in the experiment.</p> <p>[4] LAVES 2007: Tierschutzleitlinie für die Milchkuhhaltung. LAVES, Tierschutzdienst, Arbeitsgruppe Rinderhaltung. Available under: https://www.ml.niedersachsen.de/download/72925/Tierschutzleitlinie_fuer_die_Milchkuhhaltung.pdf</p>
Ethics oversight	The experiment was planned in close cooperation with the animal welfare officer of the BfR. The experiment was in accordance with relevant guidelines and regulations and was approved by the Regional Office for Health and Social Affairs Berlin (LAGeSo, approval number G 0239/17).

Note that full information on the approval of the study protocol must also be provided in the manuscript.